Landos’ advanced AI-based integrated computational LANCE platform explores immune cell activity and metabolic function, a distinct approach that has verified three novel pathways: LANCL2, NLRX1 and PLXDC2. Activation of the LANCL2 pathway amplifies the immunosuppressive functions of T regulatory cells while decreasing production of inflammatory cytokines such as TNF-alpha. The NLRX1 pathway, provides a mechanism for modulating immune functions to complement or act in combination with other related treatments. The PLXDC2 pathway, when activated, leads to the production of IL-10 and prevention of oxidative stress.
Landos Biopharma is a late clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune disease. The Company’s lead product candidate, omilancor (BT-11), is a small molecule that targets a novel immunometabolic pathway within the gastrointestinal tract, potentially providing a more effective treatment and an improved patient tolerability profile.
The Company reported final results from its Phase 2 trial of omilancor for patients with mild-to-moderate ulcerative colitis (UC) and expects to initiate a Phase 3 trial in 2021. In May 2021, Landos initiated a Phase 2 trial of omilancor in a second indication – moderate-to-severe Crohn’s disease (CD).
For chronic conditions such as inflammatory bowel disease, current treatments bear adverse side effects and impact on patients’ quality of life. Landos Biopharma’s translational research is focused on identifying more precise targets for treating ulcerative colitis and Crohn’s disease. Landos’ therapeutic approach aims to enhance the treatment paradigm of debilitating autoimmune disease by preventing or reducing patient susceptibility to infections and other side effects common with current therapies.